- June 22, 2021
- Posted by: Stratford Team
- Category: Business
No Comments
AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid intoxication and substance addiction, today reported recent business highlights and announced financial results for the fiscal year 2021 third quarter, ended March 31, 2021.
Business highlights for the quarter and recent weeks include the following:
- Completed an initial public offering (IPO) of 3,078,224 shares of common stock at $7.00 per share resulting in gross cash proceeds to the Company of approximately $20.2 million before deducting underwriting discounts, commissions and expenses. On May 7, 2021, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol ANEB.
- Management believes IPO net proceeds of $19.0 million provide adequate funding for the Company’s planned business operations…
